Open AccessEfficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data
Author(s) -
Pavel Mazin,
Н. К. Мазина
Publication year - 2018
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2017-13-4-91-100
Subject(s) - cabazitaxel , enzalutamide , docetaxel , prostate cancer , medicine , adverse effect , oncology , clinical trial , pharmacology , cancer , androgen deprivation therapy , androgen receptor